Treatment of Chronic Prostatitis with Phosphodiesterase Type 5 Inhibitors

Our major aim was to systematically study the effectiveness of phosphodiesterase type 5 inhibitors in treating chronic prostatitis stage III and performed meta-analysis evaluate changes occurred posttreatment scores National Institutes Health symptom index, international index erectile function prostate score. This conducted according preferred reporting items for systematic reviews meta-analyses guidelines. Comprehensive research by using online resources like PubMed Wiley library database gather relevant literature produced from y 2010 2022. Two authors were assigned independently collect information including author name, region study, design, treatment, publication year, sample size, voiding parameters, inclusion exclusion criteria, urological conditions, drug type, score, etc. In final screening 17 studies found. Out these 17, contained surgical procedure while 4 narrative analysis. One incomplete regarding information. Finally, 7 included Total 584 patients involved selected studies. Three out seven are Italy two Japan one Korea Egypt respectively. Most used tadalafil monotherapy placebo-controlled trial. A significant difference pain score domain observed after consuming mg monotherapy. Everyday consumption oral gave positive outcomes terms voiding. majority Hence, alone can be treat prostatitis.